Sage Journals: Discover world-class research

Abstract

The aim was to investigate blood concentrations of copeptin and the prognostication in 24 versus 48 hours of targeted temperature management (TTM) in patients resuscitated after out-of-hospital cardiac arrest. This is an exploratory biomarker substudy of the trial entitled; “Targeted temperature management for 48 vs 24 hours and neurologic outcome after out-of-hospital-cardiac-arrest: A randomized clinical trial.” Patients were randomized to target temperature of 33°C ± 1°C for 24 (TTM24) or 48 (TTM48) hours. The primary outcome was copeptin concentrations compared with TTM at admission, 24, 48, and 72 hours (t24, t48, and t72) after reaching target temperature. Secondary outcomes were the association between copeptin and cerebral performance category (CPC) score after 6 months, and copeptin level between cerebral or noncerebral causes of death. Blood samples from 117 patients were analyzed from two Scandinavian sites. No significant differences in copeptin concentrations were found between TTM24 versus TTM48 at admission 211.3 μg/L (148–276.6) versus 179.8 μg/L (127–232.6) (p = 0.45), t24: 23.3 μg/L (16.5–30.2) versus 18.6 μg/L (13.3–23.9) (p = 0.25), t48: 28.8 μg/L (20.6–36.9) versus 19.7 μg/L (14.3–25.1) (p = 0.06), and t72: 23.3 μg/L (13.8–26.8) versus 31.6 μg/L (22–41.2) (p = 0.05). Copeptin concentrations were significantly higher in poor neurological outcome group at t24, t48, and t72 (p < 0.01), but not at admission (p = 0.19). The prognostic ability of copeptin (area under the receiver operating characteristic curve) was at admission: 0.59 (95% confidence intervals: 0.46–0.72), t24: 0.74 (0.63–0.86), t48: 0.8 (0.7–0.9), and t72: 0.76 (0.65–0.87). Copeptin levels were not significantly different in noncerebral compared with cerebral causes at admission: p = 0.41, t24: p = 0.52, t48: p = 0.15, and t72: p = 0.38. There were no differences in the level of copeptin in TTM24 versus TTM48. Blood concentrations of copeptin were associated with CPC at 6 months, and no association between levels of copeptin and cerebral versus noncerebral causes of death was observed.

Get full access to this article

View all access options for this article.

References

Annborn

, Dankiewicz

, Nielsen

, et al. CT-proAVP (copeptin), MR-proANP and peroxiredoxin 4 after cardiac arrest: release profiles and correlation to outcome. Acta Anaesthesiol Scand, 2014; 58:428–436.

Annborn

, Fredrik

, Josef

, et al. The combination of biomarkers for prognostication of long-term outcome in patients treated with mild hypothermia after out-of-hospital cardiac arrest—a pilot study. Ther Hypothermia Temp Manag, 2016; 6:85–90.

Broessner

, Hasslacher

, Beer

, et al. Outcome prediction and temperature dependency of MR-proANP and Copeptin in comatose resuscitated patients. Resuscitation, 2015; 89:75–80.

Chamberlain

, Cummins

, Abramson

, et al. Recommended guidelines for uniform reporting of data from out-of-hospital cardiac arrest: the “Utstein style.” Prepared by a Task Force of Representatives from the European Resuscitation Council, American Heart Association, Heart and Stroke Foundation of Canada, Australian Resuscitation Council. Resuscitation, 1991; 22:1–26.

Duez

CHV

, Grejs

, Jeppesen

, et al. Neuron-specific enolase and S-100b in prolonged targeted temperature management after cardiac arrest: A randomised study. Resuscitation, 2018; 122:79–86.

Düring

, Annborn

, Cronberg

, et al. Copeptin as a marker of outcome after cardiac arrest: A sub-study of the TTM trial. Crit Care, 2020; 24:185.

Kirkegaard

, Søreide

, de Haas

, et al. Targeted temperature management for 48 vs 24 hours and neurologic outcome after out-of-hospital cardiac arrest: A randomized clinical trial. JAMA, 2017; 318:341–350.

Nickel

, Ruedinger

, Misch

, et al. Copeptin and peroxiredoxin-4 independently predict mortality in patients with nonspecific complaints presenting to the emergency department. Acad Emerg Med, 2011; 18:851–859.

Nielsen

, Wetterslev

, Cronberg

, et al. Targeted temperature management at 33 degrees C versus 36 degrees C after cardiac arrest. N Engl J Med, 2013; 369:2197–2206.

10.

Nolan

, Soar

, Cariou

, et al. European Resuscitation Council and European Society of Intensive Care Medicine 2015 guidelines for post-resuscitation care. Intensive Care Med, 2015; 41:2039–2056.

11.

Ostadal

, Kruger

, Zdrahalova

, et al. Blood levels of copeptin on admission predict outcomes in out-of-hospital cardiac arrest survivors treated with therapeutic hypothermia. Crit Care, 2012; 16:R187.

12.

Ristagno

. Latini R, Plebani M, et al. Copeptin levels are associated with organ dysfunction and death in the intensive care unit after out-of-hospital cardiac arrest. Crit Care, 2015; 19:1–8.

13.

Stammet

, Collignon

, Hassager

, et al. Neuron-specific enolase as a predictor of death or poor neurological outcome after out-of-hospital cardiac arrest and targeted temperature management at 33 degrees C and 36 degrees C. J Am Coll Cardiol, 2015; 65:2104–2114.

14.

Stammet

, Dankiewicz

, Nielsen

, et al. Protein S100 as outcome predictor after out-of-hospital cardiac arrest and targeted temperature management at 33°C and 36°C. Crit Care, 2017; 21:153.

15.

Voors

, von Haehling

, Anker

, et al. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: Results from the OPTIMAAL study. Eur Heart J, 2009; 30:1187–1194.

16.

Winther

, Brynildsen

, Høiseth

, et al. Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: Data from the ACE 2 study. Respir Res, 2017; 18:184.

Copeptin as a Prognostic Marker in Prolonged Targeted Temperature Management After Out-of-Hospital Cardiac Arrest

Abstract

Get full access to this article

References